Compare GBX & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBX | VCEL |
|---|---|---|
| Founded | 1974 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1996 | 1996 |
| Metric | GBX | VCEL |
|---|---|---|
| Price | $52.35 | $33.21 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $49.00 | ★ $58.50 |
| AVG Volume (30 Days) | 205.9K | ★ 527.5K |
| Earning Date | 04-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | 28.02 | ★ 60.00 |
| EPS | ★ 1.14 | 0.32 |
| Revenue | ★ $3,240,200,000.00 | $276,259,000.00 |
| Revenue This Year | N/A | $19.10 |
| Revenue Next Year | $1.64 | $17.95 |
| P/E Ratio | ★ $44.02 | $98.34 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $37.77 | $29.24 |
| 52 Week High | $59.19 | $48.75 |
| Indicator | GBX | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.71 | 44.56 |
| Support Level | $44.64 | $31.24 |
| Resistance Level | $54.15 | $38.48 |
| Average True Range (ATR) | 1.41 | 1.36 |
| MACD | -0.41 | 0.01 |
| Stochastic Oscillator | 39.02 | 52.77 |
Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.